DOI:
10.1055/s-00000072
Seminars in Reproductive Medicine
LinksClose Window
References
Schütt B, Kaiser A, Schultze-Mosgau MH. , et al.
Pharmacodynamics and safety of the novel selective progesterone receptor modulator vilaprisan: a double-blind, randomized, placebo-controlled phase 1 trial in healthy women.
Hum Reprod 2016;
31 (08) 1703-1712
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.